Press Releases | American Food & Beverage Online

Explore more publications!

Press Releases

Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial

8 hours ago

Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial

GlobeNewswire, Inc.

Delaware Confirms State’s First Case of Chronic Wasting Disease in Wild White-tailed Deer

5 hours ago

Delaware Confirms State’s First Case of Chronic Wasting Disease in Wild White-tailed Deer

Department of Natural Resources and Environmental Control - Delaware

Owner: American Government

Department of Natural Resources and Environmental Control - Delaware

Gov't Institution

Owned By	American Government
Year Founded	1979
Website	dnrec.alpha.delaware.gov
Domain Registration Year	Indeterminate
Access Type	open
Publication Location	United States, Delaware, Dover
Owner Country	United States

We welcome your feedback!
If you have comments or corrections, let us know.

Delaware Confirms State’s First Case of Chronic Wasting Disease in Wild White-tailed Deer

5 hours ago

Delaware Confirms State’s First Case of Chronic Wasting Disease in Wild White-tailed Deer

Division of Community Affairs - Delaware

Owner: American Government

Division of Community Affairs - Delaware

Gov't Institution

Owned By	American Government
Year Founded	Indeterminate
Website	news.delaware.gov
Domain Registration Year	Indeterminate
Access Type	open
Publication Location	United States, Delaware, Dover
Owner Country	United States

We welcome your feedback!
If you have comments or corrections, let us know.

Delaware Confirms State’s First Case of Chronic Wasting Disease in Wild White-tailed Deer

5 hours ago

Delaware Confirms State’s First Case of Chronic Wasting Disease in Wild White-tailed Deer

Division of Community Affairs - Delaware

Owner: American Government

Division of Community Affairs - Delaware

Gov't Institution

Owned By	American Government
Year Founded	Indeterminate
Website	news.delaware.gov
Domain Registration Year	Indeterminate
Access Type	open
Publication Location	United States, Delaware, Dover
Owner Country	United States

We welcome your feedback!
If you have comments or corrections, let us know.

LifeVantage Receives U.S. Patent for Healthy Glow Essentials Stack

8 hours ago

LifeVantage Receives U.S. Patent for Healthy Glow Essentials Stack

GlobeNewswire, Inc.

5 hours ago

Remix Therapeutics Announces Oral Presentation of First-in-Class Small Molecule MYB mRNA Degrader REM-422 Phase 1/2 ARIA Trial Results at the 2026 American Society of Clinical Oncology Annual Meeting

GlobeNewswire, Inc.

Fischer Sciences Launches Code of Culture Probiotics Across U.S. & Canada Amid Rising Consumer Demand for whole food probiotics

11 hours ago

Fischer Sciences Launches Code of Culture Probiotics Across U.S. & Canada Amid Rising Consumer Demand for whole food probiotics

GlobeNewswire, Inc.

6 hours ago

Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026

GlobeNewswire, Inc.

Quantumtronix Inc. Announces U.S. Provisional Patent Filings and Commercial Launch of 'bestn' Consumer Wellness Platform

Apr. 20, 2026

Quantumtronix Inc. Announces U.S. Provisional Patent Filings and Commercial Launch of 'bestn' Consumer Wellness Platform

EIN Presswire

BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma

Apr. 20, 2026

BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma

GlobeNewswire, Inc.

United States Sodium Erythorbate Market Accelerates with Archer Daniels Midland, Cargill, and Jungbunzlauer

Apr. 20, 2026

United States Sodium Erythorbate Market Accelerates with Archer Daniels Midland, Cargill, and Jungbunzlauer

EIN Presswire

Apr. 20, 2026

PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

GlobeNewswire, Inc.

Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development

Apr. 20, 2026

Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development

GlobeNewswire, Inc.

Apr. 20, 2026

Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care

GlobeNewswire, Inc.

This Earth Day, What’s on Your Plate Matters: Study Shows Tofu Packs a Powerful Environmental Punch

Apr. 20, 2026

This Earth Day, What’s on Your Plate Matters: Study Shows Tofu Packs a Powerful Environmental Punch

EIN Presswire

The MOG Project Applauds Hoffmann-LaRoche & Genetech Clinical Trial That May Signal First Approved Therapy for MOGAD

37 minutes ago

The MOG Project Applauds Hoffmann-LaRoche & Genetech Clinical Trial That May Signal First Approved Therapy for MOGAD

EIN Presswire

4 hours ago

ECI Software Solutions Announces Ambassador Community to Amplify Industry Voices and Promote Shared Growth

EIN Presswire

Global Organic Pigments Market Highlights Mexico’s Manufacturing Surge as BASF Clariant & DIC Drive Leadership

Apr. 20, 2026

Global Organic Pigments Market Highlights Mexico’s Manufacturing Surge as BASF Clariant & DIC Drive Leadership

EIN Presswire

Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®

Apr. 20, 2026

Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®

GlobeNewswire, Inc.

Apr. 20, 2026

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

GlobeNewswire, Inc.